Literature DB >> 1385103

Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells.

S G Ren1, S Ezzat, S Melmed, G D Braunstein.   

Abstract

As the somatostatin analog octreotide suppresses pituitary GH secretion and circulating IGF-1 levels, we examined its effects on human hepatoma (hep G2) cells which selectively express IGFBP-1. Octreotide (60 nM) stimulated IGFBP-1 up to 4.1-fold (p < 0.001 after 24 hrs). Induction of IGFBP-1 was first detectable after 12 hrs of 6 nM octreotide (1.5-fold, p < 0.03), and was confirmed by ligand blotting. Cholera toxin and forskolin induced IGFBP-1 independently and were also additive with octreotide. IGFBP-1 mRNA expression was induced 2.7-fold by octreotide. Thus, octreotide induces basal and stimulated IGFBP-1 in hepatocytes independently of insulin and GH. As IGFBP-1 may regulate peripheral IGF-1 action, induction of IGFBP-1 represents a novel pituitary-independent mechanism for octreotide action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385103     DOI: 10.1210/endo.131.5.1385103

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.

Authors:  C Invitti; L Fatti; M G Camboni; L Porcu; L Danesi; G Delitala; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

2.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

3.  Aging and the Mammalian regulatory triumvirate.

Authors:  C David Rollo
Journal:  Aging Dis       Date:  2010-09-10       Impact factor: 6.745

Review 4.  A risk-benefit assessment of octreotide in the treatment of acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

5.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma.

Authors:  K Saito; S Inoue; T Saito; S Kiso; N Ito; S Tamura; H Watanabe; H Takeda; H Misawa; H Togashi; Y Matsuzawa; S Kawata
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

7.  Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?

Authors:  Kiki Pistevou-Gompaki; Nikos Eleftheriadis; Damianos Eleftheriadis; Christos Papaloukas; Apostolos Hatzitolios
Journal:  Clin Med Oncol       Date:  2008-05-13

Review 8.  Targeting the IGF-1R: The Tale of the Tortoise and the Hare.

Authors:  Caitrin Crudden; Ada Girnita; Leonard Girnita
Journal:  Front Endocrinol (Lausanne)       Date:  2015-04-27       Impact factor: 5.555

9.  Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.

Authors:  G Verset; C Verslype; H Reynaert; I Borbath; P Langlet; A Vandebroek; M Peeters; G Houbiers; S Francque; M Arvanitakis; J-L Van Laethem
Journal:  Br J Cancer       Date:  2007-08-07       Impact factor: 7.640

Review 10.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.